Showing 951-960 of 19239 results for "".
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/Exploring CETP inhibition as the next breakthrough in lipid lowering, cardiologists highlight mechanisms, trials, and its role as a future CV therapy.Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin InhibitorsIgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/Examine updated KDIGO 2025 IgAN guidelines and the new approach to managing proteinuria and slowing kidney function decline.RSV in Infants and Young Children: Are You Taking It Seriously Enough?
https://reachmd.com/programs/cme/RSV-in-Infants-and-Young-Children-Are-You-Taking-It-Seriously-Enough/39306/Explore RSV prevention strategies in infants, including maternal immunization and monoclonal antibodies, aligned with current AAP guidelines.APOC3 Inhibition: A Novel Approach to Lowering TGs
https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
https://reachmd.com/programs/cme/safety-of-cdk46-inhibitors-anticipation-prevention-and-management-of-adverse-events/39799/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.CETP Inhibition and Obicetrapib: A New Era in Lipid Management
https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-and-obicetrapib-a-new-era-in-lipid-management/37123/CETP Inhibition and Obicetrapib: A New Era in Lipid ManagementBreaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
https://reachmd.com/programs/cme/breaking-down-the-benchmarks-pivotal-data-on-first-line-cdk46-inhibitors/39798/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.From Image to Intervention: Integrating the Diagnosis into Specialty Lens Designs and Corneal Rehabilitation
https://reachmd.com/programs/empower/from-image-to-intervention-integrating-the-diagnosis-into-specialty-lens-designs-and-corneal-rehabilitation/39289/How to keep patients informed across the continuum of care.Increased Risk for Chronic Opioid Use After Surgery
https://reachmd.com/programs/the-jama-report/increased-risk-chronic-opioid-use-after-surgery/8236/New research shows that some patients undergoing common surgical procedures may be at increased risk for chronic opioid use months after surgery.